Skip to main content
Caplight Logo









Prosoma

Prosoma

Private
LondonHealthcare & Life Scienceshttps://www.prosoma.com/

Last Round

Series A

Jan 20, 2025

Total Funding Raised

$9.87M

Company Overview

Prosoma is a health technology company that develops digital therapeutics and behavioral support platforms for cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Medical Devices, Patient Engagement, Telemedicine

Business Model

B2G

Customer Profile

Government Contracts, Subscription SaaS

AI Layer

Application

Keywords

digital therapeuticsDTxpsycho-oncologycancer patient supportDiGADigital Health Applicationsprescription digital therapeuticSoftware as a Medical DeviceSaaMDprescription appCognitive Behavioral TherapyCBTcancer support appbehavioral healthmental health supportpatient engagement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prosoma Comparables

Compare Prosoma with similar companies based on industry and business-model similarity.

Prosoma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fosanis GmbH
85%
Tired of Cancer BV
83%
AptarGroup
77%

Prosoma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 20, 2025
SeedDec 22, 2022
GrantDec 1, 2021

Key People

Founding team and executive leadership

Andrzej Jończyk

Co-Founder, Chief Strategy Officer Head Of USA

Founding Team

Jakub Kuziela

CFO COO

Executive Team

Prosoma Investors

Notable investors and investment history

Prosoma investors
InvestorRounds
Convergence Partners AGSeries A
PomerangelsSeed
YouNick MintSeed
Impact VenturesSeries A
EIT HealthGrant
BalnordSeed
Smartlink PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 59% MoM.

  • Sep 9, 2025

    Secured $586K in grant funding.

Recent news

Latest coverage and updates

  • is_developingJul 20, 2026

    Prosoma is developing digital health solutions for oncology patients on Jul 1st '26.

Prosoma Filings

Explore SEC and related filing metadata, where available.

Prosoma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Prosoma's valuation, stock price, and market status.

Is Prosoma a public or private company?

Prosoma is a private company.

What is the current stock price of Prosoma?

Prosoma is a private company with no public stock price. No recent secondary market data is available.

How much is Prosoma worth (valuation)?

Valuation information for Prosoma is not publicly available.

Can I buy Prosoma stock?

Prosoma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Prosoma's last funding round?

Prosoma's most recent funding round was Grant on September 9, 2025.

Who are the main investors in Prosoma?

Key investors in Prosoma include YouNick Mint, Impact Ventures, Verge HealthTech Fund, Simpact Ventures, Impact Ventures.

Will Prosoma IPO soon?

No public IPO plans have been announced for Prosoma.

How can I track Prosoma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prosoma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range25
Year Founded2018
Last FundingJan 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?